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Abstract 
Background: Long intergenic non-coding RNAs (lncRNAs) are a class of non-coding RNAs that are involved in gene 
expression regulation. Taurine up-regulated gene 1 (TUG1) is a cancer progression related lncRNA in some tumor 
oncogenesis; however, its role in colorectal cancer (CRC) remains unclear. In this study, we determined the expression 
patterns of TUG1 in CRC patients and explored its effect on CRC cell metastasis using cultured representative CRC cell 
lines.
Methods: The expression levels of TUG1 in 120 CRC patients and CRC cells were determined using quantitative 
real-time PCR. HDACs and epithelial-mesenchymal transition (EMT)-related gene expression were determined using 
western blot. CRC cell metastasis was assessed by colony formation, migration assay and invasion assay.
Results: Our data showed that the levels of TUG1 were upregulated in both CRC cell lines and primary CRC clinical 
samples. TUG1 upregulation was closely correlated with the survival time of CRC patients. Overexpression of TUG1 in 
CRC cells increased their colony formation, migration, and invasion in vitro and promoted their metastatic potential 
in vivo, whereas knockdown of TUG1 inhibited the colony formation, migration, and invasion of CRC cells in vitro. It is 
also worth pointing out that TUG1 activated EMT-related gene expression.
Conclusion: Our data suggest that tumor expression of lncRNA TUG1 plays a critical role in CRC metastasis. TUG1 
may have potential roles as a biomarker and/or a therapeutic target in colorectal cancer.
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Background
Colorectal cancer (CRC) remains a primarily world-wide 
health concern in spite of significant improvements in its 
diagnosis and therapy modalities. Over 1.2 million new 
CRC cancer cases and 608,700 deaths are recorded annu-
ally [1]. Historically, comprehensive cancer treatment in 
cases of cancer metastases has always been very challeng-
ing [2]. Currently, the need to elaborate knowledge on the 
underlying molecular mechanisms for cancer metastasis 
in CRC is urgently needed.
Mammalian genomes encode a wide variety of conserved 
non-coding RNA transcripts [3, 4]. In addition to classical 
‘housekeeping’ RNAs (such as ribosome RNAs, transfer 
RNAs, and others) and widely-defined microRNAs, long 
non-coding RNAs (lncRNAs) have recently been identi-
fied as one of fraction of untranslated RNA molecules. 
lncRNAs, transcribed by RNA polymerase II (RNA pol 
II), are characterized by lengths of 200 nucleotides to ~100 
kilobases (kb) and by their lack of a significant open read-
ing frame [3]. These mRNA-like molecules are pervasively 
transcribed and roughly classified as antisense, based on 
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exhibit cis- or trans- regulatory capabilities for gene expres-
sion. Gene expression patterns indicate that these lncRNAs 
are implicated in diverse biological processes, includ-
ing nuclear architecture, regulation of gene expression, 
immune surveillance, or embryonic stem cell pluripotency. 
Recently, evidence revealing the molecular mechanisms 
by which these RNA species function has provided some 
insight into the functional roles they may play in tumo-
rigenesis [6]. Aberrant lncRNA expression participates in 
carcinogenesis by disrupting major biological processes, 
such as redirecting chromatin remodeling complexes or 
inactivating major tumor suppressor genes [6, 7].
Among these, LincRNA taurine up-regulated 
gene 1 (TUG1; also known as TI-227H; Linc00080; 
ncRNA00080) was originally identified as a transcript 
up-regulated by taurine and is found to be expressed in 
various human cancer cell lines and tumors [8]. Upregu-
lation of the long noncoding RNA TUG1 promotes pro-
liferation and migration of esophageal squamous cell 
carcinoma [9]. Downregulation of long non-coding RNA 
TUG1 inhibits osteosarcoma cell proliferation and pro-
motes apoptosis [10]. However, the role of TUG1 in colo-
rectal cancer remains unclear. This study was established 
due to our speculation that TUG1 may have roles to play 
in the CRC pathological process.
Previously, research has found that the metastasis and 
invasion of cancer cells are common events that mediate 
changes in cellular behavior, and induce different steps in 
the metastatic cascade [11, 12]. One of the most crucial 
steps in the tumor cell metastatic cascade is the acquisi-
tion of invasive capabilities, including destroying cell–cell 
junctions, degrading the cell matrix, and activating path-
ways that control the cytoskeletal dynamics of cancer 
cells. Over the past decade, cell and tumor biologists have 
identified the key role of epithelial-mesenchymal transi-
tion (EMT)-a biological process in which epithelial cells 
lose their polarity and transition into a mesenchymal 
phenotype-in cancer cell metastasis [13]. Evidence sug-
gests that EMT enhances tumor cell invasion in response 
to environmental triggers, augments invasive functions, 
and also contributes to cell growth and survival [14, 15].
In preliminary experiments, we found that upregulated 
UTR1 expression in metastatic CRC cell lines predicted poor 
survival for CRC patients. This current study was designed 
to search the evidence supporting a role for TUG1 in the 
metastasis of CRC in representative CRC cell lines. We fur-
ther attempted the preliminary exploration of the possible 
association of EMT-related gene expression by TUG1.
Methods
Clinical samples
We obtained paired CRC tumor samples (bulk samples) 
and adjacent non-tumor colorectal tissues from 120 
patients who had undergone gastrointestinal surgery 
between 2008 and 2013 at the First Affiliated Hospital of 
Zhengzhou University, China. All specimens were imme-
diately frozen in liquid nitrogen and stored at 80 °C until 
total RNA extraction. Written informed consent was 
obtained from all patients. No patient received chemo-
therapy or radiotherapy before surgery. The follow-up 
periods ranged from 2 months to 5 years, with a mean of 
3 years. Our study was approved by the Research Ethics 
Committee of Zhengzhou University.
Cell lines and cultivation
Human colorectal cancer cell lines including SW480, 
HCT116, HT29, SW620, and LOVO, were obtained from 
the Key Laboratory of Cancer Prevention and Interven-
tion, Cancer Institute, The Affiliated Hospital, Zheng-
zhou University School of Medicine, Zhengzhou, China. 
The SW480, SW620, and LOVO cell lines were cultured 
in L-15 (with 10 % FBS and 1 % streptomycin/penicillin); 
HCT-116 cell lines were cultured in McCoy’s 5A (with 
10  % FBS and 1  % streptomycin/penicillin); and HT-29 
cell lines were cultured in RPMI-1640 (with 10  % FBS 
and 1  % streptomycin/penicillin). Normal human colo-
rectal cells were purchased from the American Type Cul-
ture Collection and cultured in RPMI1640 supplemented 
with 10 % FBS and 2 mM l-Glutamine (Gibco). All cell 
lines were maintained at 37 °C and 5 % CO2 in an incu-
bator, and passaged with 0.25 % trypsin (Sigma, St Louis, 
MO, USA) in 0.2  mol/l phosphate-buffered saline (PBS; 
Sigma). The study was approved by the ethics committee 
of the Cancer Institute, The Affiliated Hospital, Zheng-
zhou University School of Medicine, Zhengzhou, China.
Real‑time quantitative PCR
Total RNA was extracted from colorectal tumor sam-
ples and CRC cell lines using TRIzol reagent (Inv-
itrogen, USA) according to the manufacturer’s 
protocol. Complementary DNA was synthesized from 
total RNA with the Revert Aid™ First Strand cDNA 
Synthesis Kit (Thermo Scientific, USA). The primer 
sequences were as follows: TUG1 forward primer: 
5c-TAGCAGTTCCCCAATCCTTG-3′, reverse primer: 
5′-CACAAATTCCCATCATTCCC-3′; GAPDH for-
ward primer: 5′-CGCTCTCTGCTCCTCCTGTTC-3′, 
GAPDH reverse primer: 5′-ATCCGTTGACTCCGACC-
TTCAC-3′. The PCR was performed in a total reaction 
volume of 20  ml and was completed in the ABI PRISM 
7000 Fluorescent Quantitative PCR System (Applied Bio-
systems, Foster City, CA, USA). GAPDH was used as an 
internal control. The PCR cycling parameters were: one 
denaturation step of 10 min at 95 °C; 40 cycles, with one 
cycle consisting of 15 s at 95 °C, 20 s at 55 °C, and 30 s at 
70 °C. The median in each triplicate was used to calculate 
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the relative TUG1 expression level using the comparative 
DCt method (value of 2−DCt(TUG1-GAPDH)). Expression fold 
changes were calculated using 2−DDCt methods.
Protein isolation and western blotting
For the protein expression analyses, standard western 
blot assay was carried out. Cultured or transfected cells 
were washed twice with cold phosphate-buffered saline 
(PBS) and were lysed with iced RIPA buffer containing 
1  % PMSF (KeyGen, Nanjin, China). After total protein 
detection using a BCA kit (Beyotime, Shanghai, China), 
protein lysates were separated on 10  % SDS polyacryla-
mide gel, transferred to PVDF membranes, and blocked 
in 0.1  % Tween 20 and 5  % skim milk protein in Tris 
Buffer Saline at room temperature for 2 h. Target proteins 
were probed with rabbit anti-HDAC1 antibody (1:800; 
Proteintech Corporation, USA), rabbit anti-HDAC2 
antibody and rabbit anti-HDAC3 monoclonal antibody 
(1:1000; Bioworld Corporation, USA), and mouse anti-
E-cadherin, N-cadherin, fibronectin, vimentin (1:1000; 
Abcam, USA), and rabbit anti-β-Actin antibody (1:2000; 
acted as an internal control, Zhongshan, Inc., Beijing, 
China) overnight at 4  °C. The membranes were washed 
twice and visualized with horseradish peroxidase (HRP)-
conjugated secondary antibodies for 2 h. Tagged proteins 
were detected by enhanced chemiluminescence (Key-
Gen, Nanjing, China).
Plasmid and lentivirus vector
Ectopic expression of TUG1 in cells was realized through 
pcDNA-TUG1 transfection. The TUG1 sequence was 
synthesized and subcloned into the pCDNA3.1 (Invitro-
gen, Shanghai, China) vector. The empty pcDNA3.1 vec-
tor was used as a control. To assess the effect of TUG1 
on liver metastasis in vivo, TUG1 was overexpressed 
by SW480 transfecting with Lenti-GIII-CMV-Human-
TUG1 Lentivirus [Applied Biological Materials (ABM) 
Inc, Canada]. Following this step, the expression levels of 
TUG1 were detected by quantity real-time PCR.
Cell transfection
Plasmid vector (pcDNA-TUG1 and pCDNA3.1) or len-
tivirus vector (Lenti-GIII-CMV-TUG1 and Lenti-GIII-
CMV) were prepared using DNA Midiprep or Midiprep 
kits (Qiagen, Hilden, Germany), and were transfected into 
SW480 cells. Two individual siRNAs (TUD1-siRNA and 
HDAC1-siRNA) and negative control siRNA (silencer 
negative control siRNA) were purchased from Ambion. 
siRNA oligonucleotides (10 nmol/L) in Opti-MEM (Inv-
itrogen) were transfected into LOVO cells or SW480 
cells, respectively, using Lipofectamine RNAiMAX 
(Invitrogen) and following the manufacturer’s protocol. 
Forty-eight hours post-transfection, TUD1 and HDAC1 
expression levels were measured, and/or cell metastasis 
ability was assessed. Target sequences for siRNAs were 
as follows: TUG1-siRNA1 (sense 5′-GGGAUAUAGC-
CAGAGAACAAUUCU-A-3′, antisense 5′-UAGAAUU-
GUUCUCUGGCUAUAUCCC-3′) and HDAC1-siRNA, 
sense 5′-CCAAGTACCACAGCGATGAC-3′, and anti-
sense 5′-TGGACAGTCCTCACCAACG-3′.
Plate clone formation assay
Each well in a 6-well culture plate was seeded with 102 
cells and each group contained three wells. The cells 
were incubated at 37 °C with 5 % CO2 for 2–3 weeks and 
the medium was replaced every 3  days. The incubation 
was stopped when colony formation was visible and the 
cells were then washed twice with PBS and stained with 
Giemsa solution for 20 min. The number of colonies con-
taining 50 cells was counted under a microscope using 
the formula: plate clone formation efficiency = (number 
of colonies/number of cells inoculated) × 100 %.
Wound healing assay
SW480pcDNA-TUG1, LOVOsi-TUG1 and their corresponding 
control cells were separately seeded into 6-well plates, 
and were cultured until they were nearly 80 % confluent. 
Artificial wounds were created by scraping the monolay-
ers with a sterile 10 ml tip, and the cells were washed with 
PBS several times to remove floating cells. Representative 
images of cells migrating into the wounds were captured 
after 0 and 24 h under a microscope (200×).
Cell migration assays
Cell migration assays were performed using 24-well 
Transwell plates (8.0-μm pore membranes; Costar). 
About 1 ×  104 cells (SW480pcDNA-TUG1 or LOVOsi-TUG1) 
were loaded into the upper chambers. The lower cham-
bers were filled with a medium (plus 1  % FBS) in the 
absence (DMSO 0.2  %) or presence of SecinH3 (10, 20, 
or 40 mM). The Transwell plates were then incubated in 
a 37  °C, 5 % CO2 incubator for 48 h. After cleaning the 
cells from the upper side of the polycarbonate membrane 
and following hematoxylin–eosin staining, the polycar-
bonate membrane was cut and placed on a microscope 
slide, cover slipped, and examined under the microscope. 
The migrated cell numbers and percentages were then 
counted.
Matrigel invasion assay
The Matrigel invasion assay was done using the BD 
Biocoat Matrigel Invasion Chamber (pore size: 8  mm, 
24-well; BD Biosciences, San Jose, CA, USA) following 
the manufacturer’s protocol. Cells (5 × 104) were plated 
in the upper chamber in a serum-free medium. The bot-
tom chamber contained a medium with 10 % FBS. After 
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the 48  h incubation, the bottom of the chamber insert 
was stained with Calcein AM (Invitrogen). The cells 
that had invaded through the membrane to the lower 
surface were evaluated in a fluorescence plate reader at 
excitation/emission.
Experimental in vivo liver metastasis model
Female athymic BALB/c nude mice (aged 6  weeks) 
were purchased from the Shanghai Laboratory Animal 
Center Co. Ltd. (Shanghai, China) and maintained in 
a pathogen-free animal facility at the Laboratory Ani-
mal Research Centre of Zhengzhou University. For liver 
metastatic capacity, the spleen of BALB/c nude mice was 
injected with 1  ×  106 cells per mouse. Briefly, BALB/c 
nude mice were anesthetized by i.p. injection of Pell-
tobarbitalum Natricum, and 1  ×  106 SW480pcDNA3.1 or 
SW480pcDNA-TUG1 tumor cells in 25 ml were injected into 
the exteriorized spleen using an insulin syringe and fol-
lowing abdominal incision. Five minutes after injection, 
spleen blood vessels were ligated, and the spleen was 
removed. Finally, the abdominal wound was closed with 
staples. After 5 weeks, mice were sacrificed and their liv-
ers were removed and tumor nodules were numbered.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
5.01 software. Statistical tests for data analysis included 
the log-rank test, the Chi square test. Multivariate sta-
tistical analysis was performed using a Cox regression 
model. The quantitative data were presented as the 
mean ± standard deviations (SD). Differences were con-
sidered to be statistically significant at values of P < 0.05.
Results
Upregulation of TUG1 is correlated with CRC progression
To investigate the clinical relevance of abnormal TUG1 
expression in CRC, we collected 120 pre-frozen primary 
CRC tissue samples (Table  1), and determined TUG1 
expression levels in all of these samples using quantita-
tive real-time PCR. By data statistics and analysis, we 
observed that TUG1 expression was significantly ele-
vated in tumor tissues compared with para-tumor tissue 
(Fig. 1a), and univariate analysis revealed a close associa-
tion between high TUG1 expression and patient survival 
(Fig.  1b). These data suggest that TUG1 upregulation 
is strongly associated with the clinical progression of 
human CRC.
Possible negative regulating TUG1 expression by histone 
deacetylase
Next, we attempted to investigate the possible mecha-
nism underlying aberrant TUG1 expression in CRC. 
The five representative CRC lines of SW480, HCT116, 
HT29, SW620, and LOVO were used for following analy-
sis. We observed that TUG1 expression was significantly 
elevated in all CRC lines compared to normal colorectal 
cells (Fig. 2a). Interestingly, TUG1 expression was found 
to be 4–6 times higher than in corresponding cell lines 
(marked as control with no TSA treatment in presence 
of TSA, an inhibitor for histone deacetylase (Fig. 2b). We 
then evaluated HDAC1, HDAC2, and HDAC3 expres-
sion in these CRC lines in comparison to control and we 
found that HDAC1 expression was upregulated, while 
the expression levels of HDAC2 and HDAC3 protein 
remained unchanged in CRC cells (Fig.  2c). These data 
suggested that TUG1 expression was possibly regulated 
by abnormal expression HDAC1 expression. Thus, the 
CRC lines were used to create sub-lines with HDAC1 
stably knocked down by shRNA focusing on analysis 
of TUG1 expression. From the result, we observed that 
HDAC1 silencing induced promotion (3.4–4.0 times the 
level of the si-control) of TUG1 expression (Fig. 2d).
TUG1 promotes the aggressiveness of CRC cells in vitro
Considering that TUG1 has a strongly correlation with 
CRC pathological courses, we transfected the SW480 cell 
line with pcDNA-TUG1 and detected the effect of over-
expressed TUG1 on CRC cell metastasis capacity. The 
results showed that TUG1 overexpression induced an 
increase in colony formation (Fig.  3a) and caused a sig-
nificant facilitation of cell migration in a wound-healing 
assay (Fig.  3b). We also utilized the classical Transwell 
assay to assess the contribution of TUG1 to cell migra-
tion and invasion. As shown in Fig.  3c and d, overex-
pressed TUG1 increased migration of SW480 cells and 
enhanced cell invasion ability.
Knock‑down TUG1 suppresses CRC cell metastasis in vitro
Another CRC cell line- LOVO was used to establish 
cell subline with TUG1 stably knocked down by TUG1-
shRNA transfection with the purpose of evaluating CRC 
cell metastasis ability. The results showed that, compared 
with the si-control, TUG1 silencing reduced the number 
of colony formations (Fig. 4a). TUG1 silencing also pro-
motes cell migration showed by a wound-healing assay 
(Fig.  4a). Additionally, by classical Transwell assay, we 
observed that TUG1-shRNA interference caused signifi-
cant suppression in ability of cell migration and invasion 
as shown in Fig. 4c and d.
Inhibition of mice CRC progression by enhancing 
tumor‑expressing TUG1
Liver metastasis of colon cancer is a common clini-
cal phenomenon. Considering the identification of the 
key regulator role of TUG1 on CRC cell metastasis in 
vitro, we next established an in vivo experimental liver 
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metastasis model by injecting human SW480 CRC cells 
into the spleens of BALB/c nude mice and followed their 
ability to invade-via the portal vein-the liver to form 
metastases and then investigated whether TUG1 plays an 
important role in the liver metastasis of CRC. To define 
the relationship between TUG1 and CRC liver metastasis 
in vivo, six, 7-week-old female BALB/c nude mice in each 
group were injected with SW480pcDNA-TUG1 or SW480p-
cDNA cells into the spleen before splenectomy. After 
5  weeks, the mice were sacrificed, and the metastatic 
tumor nodules that formed in the liver were numbered. 
The data showed that metastatic tumor nodules were 
more frequently found in the livers of the SW480pcDNA-
TUG1 group than in the SW480pcDNA group (Fig. 5).
TUG1 facilitates epithelial‑mesenchymal transition (EMT) 
in CRC cell lines
EMT is an important factor in cell invasion. Thus, we 
next determined whether EMT markers were altered in 
our model. The expression of E-cadherin, N-cadherin, 
vimentin, and Fibronectin protein level was analyzed 
by Western blot. By data, we found that the expression 
of N-cadherin, vimentin and Fibronectin was increased 
while E-cadherin expression was decreased, in SW480-
TUG1 cells (Fig.  6a), whereas the opposite results were 
obtained when TUG1 was knocked down in LOVO cells 
(Fig. 6b).
Discussion
Recent evidence has shown that lncRNAs play an impor-
tant role in cancer pathogenesis, and could provide new 
insights into the biology of this disease [7]. Although 
lncRNAs may have an impact on various human diseases, 
including cancer, the basis of their molecular mechanism 
is still beginning to be elucidated [16]. Likewise, no data 
are available for the role of them played during the CRC 
pathological process. One of these lncRNAs is metasta-
sis-associated TUG1. Although TUG1 is recognized as 
the highly conserved nuclear lncRNA and is a predic-
tive marker for metastasis development in human cancer 
[17], its role in CRC metastasis remains unclear.
In our current study, we analyzed the behavior of 
TUG1 in CRC metastasis. Initially, we observed that 
TUG1 expression levels in CRC tissues were higher 
than those in corresponding para-carcinoma tissues. As 
for clinicopathologic variables, TUG1 expression levels 
Table 1 TUG1 (taurine upregulated gene 1) expression and clinicopathologic factors (n = 120)
Tumor high expression, the relative expression level of TUG1 is fivefold than para-carcinoma tissue. Tumor low expression, the relative expression level of TUG1 is less 
than fivefold than para-carcinoma tissue
*Difference is statistically significant
Characteristics All cases TUG1 expression levels
Tumor high expression Tumor low expression P value
Age 0.512
 <60 61 38 23
 ≥60 59 33 26
Gender 0.761
 Male 80 60 20
 Female 40 29 11
Grade 0.027*
 Well and moderately 86 14 72
 Poorly differentiated 34 20 14
Depth of tumor 0.034*
 m, sm, mp 30 27 3
 ss, se, si 90 65 25
Lymph node-metastasis 0.013*
 Negative 70 23 47
 Positive 50 35 15
Liver metastasis
 Negative 95 25 70 0.01*
 Positive 25 18 7
Dukes’ stage
 A and B 69 50 19 0.234
 C and D 51 36 15
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were speculated to be linked to colonic carcinogenesis. 
We thus chose five representative cell lines of CRC and 
investigated TUG1 levels with a non-tumoral colorectal 
cell line as control. By in vitro data, we then showed that 
TUG1 overexpression significantly enhanced tumor-like 
characteristics by increasing the colony formation, migra-
tion, and invasion of CRC cells. Accordingly, the opposite 
results were obtained when TUG1 was knocked down. 
These results indicate that TUG1 might play a key role in 
promoting metastasis of CRC, which was further proven 
by a mice liver metastasis model in which TUG1 overex-
pression significantly increased the number of metastatic 
tumor nodules in the liver. Our study is consistent with 
previous research revealing that the high expression of 
TUG1 in primary CRC was strongly associated with lung 
metastases [17]. Moreover, our data showed that high 
TUG1 expression in CRC tissues was closely associated 
with a decreased survival time in CRC patients. These 
multivariate analyses suggested that TUG1 might be an 
independent risk factor for CRC metastasis.
Knowledge of how lncRNAs are regulated in complex 
gene regulatory systems has attracted a lot of atten-
tion. Previously, hypermethylation of the promoter or 
the intergenic differentially methylated region has been 
found to contribute to reduced expression of lncRNA 
MEG3 in tumors, indicating that epigenetic regulation is 
also involved in the expression of these genes [18]. The 
fact that whether histone deacetylation that functioned 
as epigenetic regulatory factors manipulate the expres-
sion of TGU1 remains unknown. Our findings emphasize 
Fig. 1 TUG1 is upregulated in primary human CRC samples. a Sta-
tistical analysis was performed to present TUG1 expression in paired 
para-tumor/tumor samples in each clinical sample test. b Kaplan–
Meier curves of CRC patients with low versus high expression of 
TUG1 (n = 120, P < 0.001, log-rank test); high expression showed that 
tumor TUG1 expression is 5 times higher than para-tumor tissue; low 
expression showed that tumor TUG1 expression is 5 times lower than 
para-tumor tissue. Values represent mean ± SD. * P < 0.05 compared 
with normal tissues
Fig. 2 Enhanced expression of TUG1 by histone deacetylase inhibi-
tion. a Relative ectopic expression of TUG1 in normal colorectal cell 
(control) and colorectal cancer cell lines by using Q-RT-PCR. b Relative 
expression of TUG1 in TSA treated normal tissue (control) and colo-
rectal cancer cell lines. c Western blot analysis of HDAC1, HDAC2, and 
HDAC3 expression in normal colorectal cell (control) and colorectal 
cancer cell lines; β-actin served as a loading control. d Knock down 
of HDAC1 by si-HDAC transfection in normal colorectal cells (control) 
and colorectal cancer cell lines. e Relative expression of TUG1 in si-
HDAC treated normal colorectal cells (control) and colorectal cancer 
cell lines. The colorectal cancer cell lines containing SW480, HCT116, 
HT29, SW620, and LOVO. Values represent mean ± SD. * P < 0.05 
compared with control or si-control
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Fig. 3 Enhanced metastasis of CRC cells with overexpressed TUG1. a Representative image and number statistics for colony formation in SW480p-
cDNA and SW480pcDNA-TUG1 cells. b Wound-healing assay for motility of SW480pcDNA and SW480pcDNA-TUG1 cells. Representative pictures of one field 
at the beginning (t = 0) (left panel) and at the end of the recording (t = 12 h) (right panel) in each condition. c Representative images of transwell 
migrated cells and d invaded cells in stably transfected SW480pcDNA and SW480pcDNA-TUG1 cells and average number of migrated cells and invaded 
cells are shown in the right of (c) and (d). Values represent mean ± SD. * P < 0.05 compared with pcDNA
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that histone deacetylase is a key factor in controlling the 
expression of the lncRNA TUG1. We observed that both 
TSA (an inhibitor for histone deacetylase) and HDACs 
knockdown enhanced THG1 expression. These results, 
along with those from a recent study [19], highlight the 
role of epigenetics in regulating lncRNA transcription.
Fig. 4 Silenced TUG1 inhibited metastasis of CRC cells. a Representative image and number statistics for colony formation in LOVOsi-control and 
LOVOsi-TUG1 cells. b Wound-healing assay for motility of LOVOsi-control and LOVOsi-TUG1 cells. Representative pictures of one field at the beginning 
(t = 0) (left panel) and at the end (t = 12 h) (right panel) of the recording in each condition are shown. c Representative images of transwell migrated 
cells, and d invaded cells in stably transfected LOVOsi-control and LOVOsi-TUG1 cells and the average number of migrated cells and invaded cells are 
shown in the right of (c) and (d). Values represent mean ± SD. * P < 0.05 compared with si-control
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To explore the molecular mechanism through which 
TUG1 contributes to the invasion and metastasis of CRC 
cells, we investigated potential target proteins involved 
in cell motility and matrix invasion, such as EMT-related 
gene expression. EMT is essential for cancer cell metas-
tasis and it enhances tumor cell invasion in response to 
environmental triggers, and augments invasive functions 
and also contributes to cell growth and survival [20, 21]. 
Important hallmarks of EMT include the loss of E-cad-
herin expression and increased expression of non-epi-
thelial cadherins, such as N-cadherin and vimentin. The 
loss of E-cadherin expression is a fundamental event in 
EMT, and a crucial step in the progression of papillomas 
to invasive carcinomas [13]. Therefore, we determined 
the protein levels of these EMT-induced markers follow-
ing ectopic expression of TUG1. Our results indicated 
that TUG1 overexpression reduced E-cadherin expression 
and enhanced the expression levels of N-cadherin, vimen-
tin, and Fibronectin, whereas knockdown of endogenous 
TUG1 expression significantly abrogated these capacities. 
These data indicated that TUG1 might influence CRC 
metastasis by mediating EMT-related gene expression.
Conclusion
In summary, the expression of TUG1 was significantly 
increased in CRC tumor tissues, suggesting that its 
downregulation may be a negative prognostic factor for 
CRC patients, and indicative of poor survival rates and a 
higher risk for cancer metastasis. We showed that TUG1 
possibly regulates the invasive and metastatic ability of 
CRC cells, partially through regulation of EMT. Our find-
ings promote further the understanding of CRC patho-
genesis and development, and facilitate the development 
of lncRNA-directed diagnostics and therapeutics against 
cancers. However, the molecular mechanisms by which 
HDAC1 controls TUG1 expression and TUG1 regulates 
EMT require further investigation.
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Fig. 5 Statistics for mice metastatic nodules in vivo. Nude mice were 
injected with SW480pcDNA or SW480pcDNA-TUG1 cells and tumor nod-
ules were numbered 7 days post-transplantation. Values represent 
mean ± SD. * P < 0.05 compared with SW480-control
Fig. 6 Effect of TUG1 on EMT related-gene expression in colorec-
tal cancer cell line of SW480 and LOVO. a Western blot analysis of 
EMT-related gene expression in pcDNA-TUG1-transfected SW480 
cells. b Western blot analysis of EMT-related gene expression in si-
TUG1-transfected LOVO cells. Values represent mean ± SD. * P < 0.05 
compared with pcDNA or si-control
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